| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues, net | 635,224 | 178,238 | 134,899 | - |
| Depreciation and amortization | - | - | - | 6,714 |
| Cost of implants and other costs | 358,812 | 0 | - | - |
| Research and development | 1,004,660 | 296,860 | 161,919 | 460,138 |
| Selling, general and administrative | 1,145,353 | 1,223,321 | 886,083 | 1,192,869 |
| Depreciation and amortization | 71,986 | 71,977 | 24,843 | - |
| Change in fair value of royalty liability | - | - | -2,611 | - |
| Total operating expenses | 2,580,811 | 1,592,158 | 1,072,845 | 1,659,721 |
| Other miscellaneous expense | - | - | 59,439 | - |
| Other miscellaneous income | - | 104,890 | - | - |
| Loss from operations | -1,945,587 | -1,413,920 | -937,946 | -1,659,721 |
| Interest expense - related party | 195,515 | 164,371 | -160,128 | 158,267 |
| Grant income | - | - | 413,979 | 572,777 |
| Interest expense, net | 29,672 | 36,686 | 87,483 | 148,999 |
| Loss on settlement of debt | 0 | -55,000 | -132,514 | -123,563 |
| Grant income | 867,130 | 154,270 | - | - |
| Change in fair value of upfront purchase price liability | -1,785 | -394 | - | - |
| Change in fair value of royalty liability | 0 | 33,935 | - | - |
| Change in fair value of upfront purchase price liability | - | - | -4,500 | - |
| Other miscellaneous income | 496,927 | - | - | 4,763 |
| Total other income (expenses) | 1,137,085 | 36,644 | 86,182 | 146,711 |
| Net loss before provision for income taxes | -808,502 | -1,377,276 | -851,764 | -1,513,010 |
| Income taxes | - | 0 | - | - |
| Net loss | -808,502 | -1,377,276 | -851,764 | -1,513,010 |
| Non-controlling interest | -1,109,371 | -143,858 | 10,357 | 25,623 |
| Net loss attributable to biocorrx inc. | - | - | - | -1,487,387 |
| Net loss attributible to biocorrx, inc | -1,917,873 | -1,233,418 | -841,407 | - |
| Basic & diluted eps | - | - | - | -0.14 |
| Weighted average number of common shares outstanding, basic and diluted | - | 17,011,680 | - | - |
| Net loss per common share, basic and diluted | -0.11 | -0.07 | - | - |
| Weighted average number of common shares outstanding, basic and diluted | 18,162,783 | - | 3,552,262 | - |
BioCorRx Inc. (BICX)
BioCorRx Inc. (BICX)